IPO candidate

Singapore health group moves to US & targets IPO by 2023

Biofourmis, which uses bio-sensor technology and personalised predictive analytics, is moving to Boston after raising another $35 million. Next stop IPO.

Having completed a $35 million Series-B round of fundraising, Singapore's Biofourmis is moving Stateside, the digital therapeutics startup said on Tuesday.

¬ Haymarket Media Limited. All rights reserved.

Sign In to Your Account To Access Exclusive FinanceAsia Content!

Please sign in to your subscription to unlock full access to our premium FA resources.

Free Registration & 7-Day Trial
Register now to enjoy a 7-day free trial - no registration fees required. Click the link to get started.

Note: This free trial is a one-time offer.

Questions?
If you have any enquiries or would like a quote for a team or company licence, please contact us at [email protected]. Our subscription team will be happy to assist you.

Share our publication on social media
Share our publication on social media